Wire · opportunities
FDA Grants Final Approval to Cabozantinib Capsules Across Multiple Solid Tumor Indications
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
The FDA has granted final approval to cabozantinib capsules, branded as Omcazio, for treatment across multiple solid tumor indications including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and pancreatic neuroendocrine tumors (epNET). This approval enables broader access to this oral oncology therapy with established dosing and safety profiles.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 11 Sep 2026 and 12 Sep 2026.
◆ ◆ The Wire takeaway
Your oncology startup gains a clear path to market with FDA final approval of oral cabozantinib for multiple cancers, removing barriers in prescribing and reimbursement. Engage with clinical partners this week to prepare for faster adoption and patient access.
◆ Coverage
2 sources · first reported 11 Sep 2026 · latest 12 Sep 2026
◆ Related on Wire
◆ Topics